Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
European Commission grants marketing authorisation for pazopanib (Votrient®) in the treatment of certain advanced soft tissue sarcoma subtypes
GSK announced today the EC has granted pazopanib marketing authorisation for the treatment of aSTS who have received prior chemotherapy.
-
Regulatory update – GSK announces submissions in the EU and US for dabrafenib and trametinib
GSK announced submissions in EU & US related to single-agent use of dabrafenib & trametinib to treat BRAF V600 mutation metastatic melanoma.
-
GSK completes acquisition of Human Genome Sciences
GSK announced it has completed acquisition of HGS for US$3.6 billion equity. outstanding shares acquired for US$14.25 per share in cash.
-
GSK announces acquisition of 79% of Human Genome Sciences shares; commences subsequent offering period
GlaxoSmithKline plc (LSE: GSK) today announced the results of its initial tender offer for all outstanding shares of Human Genome Sciences.
-
Maximuscle powers Vodafone McLaren Mercedes drivers through the 2012 Formula 1™ season
Leading sports nutrition brand continues its presence with on-car logos in Hungary
-
Results announcement for the second quarter 2012
GSK delivers Q2 core EPS of 26.4p and dividend of 17p
-
GSK pre-broadcast statement on BBC Panorama: “The truth about Sports Products”, 19 July 2012
GSK issued statement in anticipation of BBC Panorama programme. The truth about sports products, scheduled to be aired this evening.
-
GlaxoSmithKline and Amicus Therapeutics expand Fabry disease collaboration
GSK & FOLD announced an expansion of their collaboration to develop the investigational pharmacological migalastat HCl for Fabry disease.
-
GlaxoSmithKline celebrates its role in supporting the biggest anti-doping operation in the history of the Olympic Games
GSK, Official Laboratory Services Provider for the London 2012 Olympic and Paralympic Games celebrating with anti-doping science campaign.
-
GSK to acquire Human Genome Sciences for US$14.25 per share in cash
GSK & HGS announced they have entered into a definitive agreement under which GSK will acquire HGS for US$14.25 per share in cash.
-
US Regulatory Update – Tykerb® (lapatinib)
GSK announced it has withdrawn a sNDA to the FDA for lapatinib with trastuzumab for HER2 (ErbB2)-positive metastatic breast cancer
-
Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV
Shionogi-ViiV announced results received from Phase III SINGLE study of dolutegravir in treatment-naive adults with HIV-1.
-
GSK announces positive data from Harmony 8 and completion of clinical registration package for albiglutide in type 2 diabetes
GSK announced data have been received from Phase III Harmony 8 study of cardiovascular safety conducted across the albiglutide programme.
-
GlaxoSmithKline concludes previously announced agreement in principle to resolve multiple investigations with US Government and numerous states
GSKannounced it has reached an agreement with the US Government, to conclude the Companys ongoing Federal government investigations.
-
GSK sets 20 July for expiration of tender offer to acquire Human Genome Sciences
GSK announced it has extended its tender offer to acquire all of the outstanding shares of HGSI for US$13.00 per share 5pm NY 20/07/12
-
GSK continues with tender offer to acquire all outstanding shares of Human Genome Sciences
GSK confirmed receiving an invitation from HGS to participate in its strategic alternatives review process which started in April.
-
GSK receives FDA approval for MenHibrix
GSK plc announced today that the US FDA has approved the vaccine MenHibrix, Haemophilus b Tetanus Toxoid Conjugate Vaccine].
-
Stiefel signs worldwide acquisition and license agreement for Toctino®
Stiefel announced it has entered into a worldwide agreement to acquire Toctino (alitretinoin) from Basilea Pharmaceutica Ltd. (Basilea).
-
GSK announces new 52-week data from phase III study of once-weekly albiglutide in type 2 diabetes
Phase III study comparing albiglutide to Lispro, were presented today at the ADA Meeting in Philadelphia, USA.
-
GSK extends tender offer for all outstanding shares of Human Genome Sciences
GSK announced it has extended its tender offer to acquire all of the outstanding shares of HGS for US$13.00 per share 5:00pm NY 29/06/12
